Emerging Treatment Options for Patients with P53-pathway-deficient CLL

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2019 Dec 17

PMID 31839919

Citations 11

Authors

Marisa J L Aitken

Hun J Lee

Sean M Post

Affiliations

Soon will be listed here.

Abstract

Over the past 40 years, p53 has been the most widely studied protein in cancer biology. Originally thought to be an oncogene due to its stabilization in many cancers, it is now considered to be one of the most critical tumor suppressors in a cell's ability to combat neoplastic transformation. Due to its critical roles in apoptosis, cell-cycle arrest, and senescence, deletions and mutations are commonly observed and are often a portent of treatment failures and poor clinical outcomes. This is particularly true in chronic lymphocytic leukemia (CLL), as patients with p53 alterations have historically had dismal outcomes. As such, the tremendous efforts made to better understand the functions of p53 in CLL have contributed substantially to recent advances in treating patients with p53-pathway-deficient CLL.

Citing Articles

Current insights and future directions of Li-Fraumeni syndrome.

Hosseini M Discov Oncol. 2024; 15(1):561.

PMID: 39404911 PMC: 11480288. DOI: 10.1007/s12672-024-01435-w.

Extracellular vesicles from type-2 macrophages increase the survival of chronic lymphocytic leukemia cells ex vivo.

Ikhlef L, Ratti N, Durand S, Formento R, Daverat H, Boutaud M Cancer Gene Ther. 2024; 31(8):1164-1176.

PMID: 38918490 PMC: 11327105. DOI: 10.1038/s41417-024-00802-7.

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.

Ali A, Mahla S, Reza V, Hossein A, Bahareh K, Mohammad H EJHaem. 2024; 5(1):191-205.

PMID: 38406506 PMC: 10887358. DOI: 10.1002/jha2.849.

In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.

Stefaniuk P, Szymczyk A, Podhorecka M J Clin Med. 2022; 11(15).

PMID: 35893374 PMC: 9332027. DOI: 10.3390/jcm11154283.

Cytotoxic Efficiency of Human CD8 T Cell Memory Subtypes.

Knorck A, Schafer G, Alansary D, Richter J, Thurner L, Hoth M Front Immunol. 2022; 13:838484.

PMID: 35493468 PMC: 9043813. DOI: 10.3389/fimmu.2022.838484.

References

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

Ding W, LaPlant B, Call T, Parikh S, Leis J, He R . Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017; 129(26):3419-3427. PMC: 5492091. DOI: 10.1182/blood-2017-02-765685. View

Di Antonio M, McLuckie K, Balasubramanian S . Reprogramming the mechanism of action of chlorambucil by coupling to a G-quadruplex ligand. J Am Chem Soc. 2014; 136(16):5860-3. PMC: 4132976. DOI: 10.1021/ja5014344. View

Maya R, Balass M, Kim S, Shkedy D, Leal J, Shifman O . ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001; 15(9):1067-77. PMC: 312683. DOI: 10.1101/gad.886901. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Coutre S, Barrientos J, Brown J, de Vos S, Furman R, Keating M . Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86. PMC: 4732460. DOI: 10.3109/10428194.2015.1022770. View

Schnaiter A, Paschka P, Rossi M, Zenz T, Buhler A, Winkler D . NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013; 122(7):1266-70. DOI: 10.1182/blood-2013-03-488197. View

Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J . Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26):3209-16. DOI: 10.1200/JCO.2011.39.2688. View

10.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

11.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

12.

Xiong S, Pant V, Suh Y, Van Pelt C, Wang Y, Valentin-Vega Y . Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010; 70(18):7148-54. PMC: 2940952. DOI: 10.1158/0008-5472.CAN-10-1457. View

13.

Woyach J, Ruppert A, Heerema N, Zhao W, Booth A, Ding W . Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26):2517-2528. PMC: 6325637. DOI: 10.1056/NEJMoa1812836. View

14.

Badoux X, Keating M, Wang X, OBrien S, Ferrajoli A, Faderl S . Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011; 117(11):3016-24. PMC: 4123386. DOI: 10.1182/blood-2010-08-304683. View

15.

Rai K, Peterson B, Appelbaum F, Kolitz J, Elias L, Shepherd L . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343(24):1750-7. DOI: 10.1056/NEJM200012143432402. View

16.

Ahn I, Underbayev C, Albitar A, Herman S, Tian X, Maric I . Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129(11):1469-1479. PMC: 5356450. DOI: 10.1182/blood-2016-06-719294. View

17.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

18.

Reiff S, Mantel R, Smith L, Greene J, Muhowski E, Fabian C . The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov. 2018; 8(10):1300-1315. PMC: 6261467. DOI: 10.1158/2159-8290.CD-17-1409. View

19.

Burger J, Landau D, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K . Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016; 7:11589. PMC: 4876453. DOI: 10.1038/ncomms11589. View

20.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View